BMY's Sprycel Label Updated - Analyst Blog

By
A A A

Bristol-Myers Squibb Company ( BMY ) and partner Otsuka America Pharmaceutical, Inc. recently announced that the label of their leukemia drug Sprycel (dasatinib) has been updated by the US Food and Drug Administration (FDA).

Following the FDA move, the US label of the drug includes three-year safety and efficacy data in patients suffering from newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). The US label of the drug also includes five-year data on CP Ph+ CML patients who are resistant or intolerant to Novartis ' ( NVS ) Glivec.

The three-year data was added to Sprycel's label on the basis of encouraging follow-up data from an open-label, randomized, international phase III study (DASISION: n=519). The study evaluated Sprycel's (100 mg, once daily) efficacy compared to Glivec as a first-line therapy in adults suffering from Ph+ CP-CML.

Sprycel's US label update for CP Ph+ CML patients resistant or intolerant to Glivec includes data up to six years following the enrollment of the last patient in the phase III dose optimization CA180-034 study.

Sprycel is already available in multiple countries for treating adults in all phases (chronic, accelerated, or myeloid or lymphoid blast phase) of Ph+ CML either resistant or intolerant to prior treatments including Glivec. Moreover, the drug is also approved as a first-line therapy for treating adults suffering from Ph+ CML in the chronic phase. The drug has also been cleared for treating adults suffering from Ph+ acute lymphoblastic leukemia who are resistant or intolerable to prior medication.

Sprycel is one of the key drugs in Bristol-Myers' product portfolio. The drug performed impressively in the first quarter of 2013 with sales climbing 24% to $287 million. We believe that the addition of long-term data to the US label of the drug further enhances its credibility.

Bristol-Myers currently carries a Zacks Rank #3 (Hold). Companies such as Santarus, Inc. ( SNTS ) and Salix Pharmaceuticals ( SLXP ) currently look more attractive with a Zacks Rank #1 (Strong Buy).



BRISTOL-MYERS (BMY): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

SALIX PHARM-LTD (SLXP): Free Stock Analysis Report

SANTARUS INC (SNTS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BMY , CP , NVS , SLXP , SNTS

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

My Career No Longer Exists
My Career No Longer Exists          

Stocks

Referenced

Most Active by Volume

105,767,201
  • $46.30 ▲ 19.98%
80,574,036
  • $15.58 ▲ 1.56%
66,424,299
  • $3.46 ▲ 1.76%
42,459,394
  • $3.82 ▲ 0.79%
36,704,800
  • $13.98 ▼ 14.02%
35,625,113
  • $74.677 ▲ 1.31%
33,067,430
  • $29.26 ▼ 0.71%
32,374,580
  • $98.15 ▼ 0.23%
As of 7/30/2014, 04:04 PM